Novartis dials down RNA research

Share this article:

Novartis is scaling down its push to develop RNA therapies. BioCentury reports that the drugmaker plans to “maintain a small group in the field and will look into partnering opportunities” but will “significantly reduce” its internal focus.

According to BioCentury, the drugmaker said RNA treatments look to be a narrow field and that the company expects to lay off some of the 26 employees dedicated to RNA research.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters